|
| Press Releases |
|
 |
|
| Friday, August 25, 2023 |
|
|
中国生物制药（1177.HK）公布2023中期业绩 |
| 中国领先的创新研发驱动型医药集团—中国生物制药有限公司（「中国生物制药」或「公司」，连同附属公司统称「集团」）（股票编号：1177）公布截至2023年6月30日止6个月（「期内」）之未经审核财务业绩。 more info >> |
|
|
中國生物製藥（1177.HK）公佈2023中期業績 |
| 中國領先的創新研發驅動型醫藥集團—中國生物製藥有限公司（「中國生物製藥」或「公司」，連同附屬公司統稱「集團」）（股票編號：1177）公佈截至2023年6月30日止6個月（「期內」）之未經審核財務業績。 more info >> |
|
|
Sino Biopharmaceutical (1177.HK) Announces 2023 Interim Results |
| Sino Biopharmaceutical Limited ("Sino Biopharmaceutical" or the "Company", together with its subsidiaries, the "Group") (HKEX:1177), a leading innovation-driven pharmaceutical conglomerate in the PRC, has announced its unaudited interim results for the six months ended 30 June 2023 (the "Period"). more info >> |
|
| Friday, March 31, 2023 |
|
|
中国生物制药（1177.HK）公布2022全年业绩 |
| 中国领先的创新研发驱动型医药集团—中国生物制药有限公司（「中国生物制药」或「公司」，连同附属公司统称「集团」）（股票编号：1177）公布截至2022年12月31日止12个月之经审核财务业绩。 more info >> |
|
|
中國生物製藥（1177.HK）公佈2022全年業績 |
| 中國領先的創新研發驅動型醫藥集團—中國生物製藥有限公司（「中國生物製藥」或「公司」，連同附屬公司統稱「集團」）（股票編號：1177）公佈截至2022年12月31日止12個月之經審核財務業績。 more info >> |
|
|
Sino Biopharm (1177.HK) Announces 2022 Annual Results |
| Sino Biopharmaceutical Limited ("Sino Biopharm" or the "Company", together with its subsidiaries, the "Group") (HKEX:1177), a leading innovation-driven pharmaceutical conglomerate in the PRC, has announced its audited financial results for the year ended 31 December 2022. more info >> |
|
| Tuesday, August 23, 2022 |
|
|
中国生物制药（1177.HK）公布2022年中期业绩，收入上升5.9%至人民币151.94亿元 |
| 中国领先的创新研发驱动型医药集团—中国生物制药有限公司（「中国生物制药」或「公司」，连同附属公司统称「集团」）（股票编号：1177）公布截至2022年6月30日止六个月（「期内」）之未经审核财务业绩。 more info >> |
|
|
中國生物製藥（1177.HK）公布2022年中期業績，收入上升5.9%至人民幣151.94億元 |
| 中國領先的創新研發驅動型醫藥集團—中國生物製藥有限公司（「中國生物製藥」或「公司」，連同附屬公司統稱「集團」）（股票編號：1177）公布截至2022年6月30日止六個月（「期內」）之未經審核財務業績。 more info >> |
|
|
Sino Biopharmaceutical (1177.HK) Announces 2022 lnterim Results, Revenue up by 5.9% to RMB15.19 billion |
| Sino Biopharmaceutical Limited ("Sino Biopharmaceutical" or the "Company", together with its subsidiaries, the "Group") (HKEX:1177), a leading innovation-driven pharmaceutical conglomerate in the PRC, has announced its unaudited Interim results for the six months ended 30 June 2022 (the "Period"). more info >> |
|
| Thursday, July 22, 2021 |
|
|
Sino Biopharmaceutical Donates Cash and Supplies Valued at RMB10 Million to Support Henan for Flood Relief and Preventing Epidemic |
| Sino Biopharmaceutical Limited ("Sino Biopharmaceutical" or the "Company", together with its subsidiaries, the "Group") (HKEX:1177), a leading and innovation-driven pharmaceutical conglomerate in the PRC, has announced the donation of cash and supplies valued at RMB10 million to support Henan for flood relief and preventing epidemic. more info >> |
|
|
|
|
|
|
|
|
|
| Latest Press Releases |
|
“双碳”下的绿色实践 看联控如何携成员企业走出自身特色
Sept 25, 2023 14:28 HKT/SGT
|
|
|
“雙碳”下的綠色實踐 看聯控如何攜成員企業走出自身特色
Sept 25, 2023 14:27 HKT/SGT
|
|
|
巨星传奇：明星IP赋能的创新型新零售玩家 浦银首予“买入”评级 目标价7.8港元
Sept 25, 2023 14:12 HKT/SGT
|
|
|
巨星傳奇：明星IP賦能的創新型新零售玩家 浦銀首予「買入」評級 目標價7.8港元
Sept 25, 2023 14:11 HKT/SGT
|
|
|
迪信通复牌在望：不止超预期复苏，更迎来业务生态升维
Sept 25, 2023 13:59 HKT/SGT
|
|
|
迪信通複牌在望：不止超預期復蘇，更迎來業務生態升維
Sept 25, 2023 13:58 HKT/SGT
|
|
|
The Philippines unveiled FSI's leading talents at WFIS Awards 2023
Sept 25, 2023 13:40 HKT/SGT
|
|
|
致力于开发中国双抗疗法的生物技术公司武汉友芝友生物于香港联交所主板正式挂牌
Sept 25, 2023 12:47 HKT/SGT
|
|
|
致力於開發中國雙抗療法的生物技術公司武漢友芝友生物於香港聯交所主板正式掛牌
Sept 25, 2023 12:46 HKT/SGT
|
|
|
A biotechnology company dedicated to developing BsAb-based therapies in China, YZY Biopharma Officially Listed on Main Board of SEHK
Sept 25, 2023 12:45 HKT/SGT
|
|
|
DOOGEE新型タフネススマートフォンとタブレットの発売：秋の冒険の理想的な相棒
Sept 25, 2023 12:00: JST
|
|
|
Value Research Center (VRC) at SSUNGA78: 'How Purpose, Value, and Impact will Drive a Sustainable Post-SDG Future'
Sept 25, 2023 3:00 JST
|
|
|
Valkyrie遊戲發佈會圓滿落幕
Sept 23, 2023 16:34 HKT/SGT
|
|
|
Valkyrie游戏发布会圆满落幕
Sept 23, 2023 16:33 HKT/SGT
|
|
|
Famous French Perfume Brand HOMFE Unveils QUEEN 55 and KING 55, Redefining Luxury
Sept 22, 2023 23:00: JST
|
|
|
|
|
More News >> |
|
|
|
|
|
